Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-center, Randomized Study to Compare Efficacy and Safety of Daptomycin to Semi-synthetic Penicillins or Vancomycin in the Treatment of Elderly Patients (Aged greater than or equal to 65 Years) With Complicated Skin and Soft Tissue Infections.

Next Previous
Trial Profile

An Open Label, Multi-center, Randomized Study to Compare Efficacy and Safety of Daptomycin to Semi-synthetic Penicillins or Vancomycin in the Treatment of Elderly Patients (Aged greater than or equal to 65 Years) With Complicated Skin and Soft Tissue Infections.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daptomycin (Primary) ; Cloxacillin; Flucloxacillin; Oxacillin; Vancomycin
  • Indications Bacteraemia; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Novartis

Most Recent Events

  • 14 Apr 2012 Additional investigational drug identified as (Flucloxacillin, Oxacillin) as reported by ClinicalTrials.gov.
  • 14 Apr 2012 Actual end date (Mar 2011) added as reported by European Clinical Trials Database record.
  • 14 Apr 2012 Planned number of patients changed from 120 to 146 as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top